Genetic-targeted therapy of thyroid cancer: A real promise

Thyroid

Volumn 19, Issue 8, 2009, Pages 805-809

  Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MOTESANIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PENDRIN; RAF PROTEIN; RAS PROTEIN; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; VIMENTIN;

CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DRUG POTENTIATION; EDITORIAL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; GENE REARRANGEMENT; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; MAP KINASE SIGNALING SYSTEM; MEDICAL ONCOLOGY; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; THYROID NEOPLASMS;

EID: 68349113557     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.1583     Document Type: Editorial

References (67)

1. Robinson MJ, Cobb MH 1997 Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180-186.
2. Kohno M, Pouyssegur J 2006 Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-211. (Pubitemid 43675585)
3. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262.
4. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
5. Xing M 2008 Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 41:1135-1146.
6. Espinosa AV, Porchia L, Ringel MD 2007 Targeting BRAF in thyroid cancer. Br J Cancer 96:16-20.
7. Nikiforov YE 2008 Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21 Suppl 2:S37-43.
8. Knauf JA, Fagin JA 2009 Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 21:296-303.
9. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt- Leopold J, Sellers WR, Rosen N 2006 BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362. (Pubitemid 43128863)
10. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD 2007 Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 92: 4712-4718. (Pubitemid 350223448)
11. Liu D, Liu Z, Jiang D, Dackiw AP, Xing M 2007 Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 92:4686-4695. (Pubitemid 350223445)
12. Leboeuf R, Baumgartner JE, BenezraM, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA 2008 BRAFV600E mutation is associated with preferential sensitivity tomitogenactivated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 93:2194-2201. (Pubitemid 351831535)
13. Liu D, Xing M 2008 Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid 18:853-864.
14. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals crosscontamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341. (Pubitemid 352789529)
15. Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR 2009 Distinct Genetic Alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid 19:825-835.
16. Henderson YC, Ahn SH, Clayman GL 2009 Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. Arch Otolaryngol Head Neck Surg 135:347-354.
17. Debnath J, Brugge JS 2005 Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5:675-688. (Pubitemid 41486361)
18. Weigelt B, Bissell MJ 2008 Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 18:311-321.
19. Martin KJ, Patrick DR, Bissell MJ, Fournier MV 2008 Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 3: e2994.
20. Casado E, De Castro J, Belda-Iniesta C, Cejas P, Feliu J, Sereno M, González-Barón M 2007 Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clin Transl Oncol 9:549-554.
21. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S 2009 Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2:18.
22. Ramalingam S, Belani CP 2007 Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets 11:245-257. (Pubitemid 46188817)
23. Heist RS, Christiani D 2009 EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10:59-68.
24. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T 2007 Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27: 3645-3649. (Pubitemid 47607514)
25. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS 2008 Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 93:611-618. (Pubitemid 351240838)
26. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R 2008 BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191-205.
27. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949.
28. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL 2009 High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15:485-491.
29. Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS, Hwang TS 2009 Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 19:137-141.
30. Oler G, Cerutti JM 2009 High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115:972-980.
31. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646-6656.
32. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 131:257-269.
33. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 927:2840-2843. (Pubitemid 47037399)
34. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, Mazzarotto R, Casara D, Nacamulli D, Mantero F, Opocher G, Busnardo B, Girelli ME 2008 Molecular characteristics in papillary thyroid cancers (PTCs) with no (131) I uptake. Clin Endocrinol (Oxf ) 681:108-116.
35. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R 2008 BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 15:511-520. (Pubitemid 351880839)
36. Espadinha C, Santos JR, Sobrinho LG, Bugalho MJ 2009 Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAF(V600E) mutation dependency. Clin Endocrinol (Oxf ) 70:629-634.
37. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379. (Pubitemid 41759286)
38. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3- CA, and AKT1. Cancer Res 69:4885-4893.
39. Watanabe R, Hayashi Y, Sassa M, Kikumori T, Imai T, Kiuchi T, Murata Y 2009 Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr J 56:407-414.
40. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 2005 The RET/PTC-RASBRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115:1068-1081. (Pubitemid 40489412)
41. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66:6521-6529. (Pubitemid 44085606)
42. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S 2006 BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147:5699-5707. (Pubitemid 44833486)
43. Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, Filetti S, Russo D, Damante G 2009 Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid 19:247-255.
44. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670. (Pubitemid 44402153)
45. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M 2006 Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 119:2322-2329. (Pubitemid 44546951)
46. Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, Teng W, Xing M 2008 Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer 113:247-255.
47. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in lowrisk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf ) 65:364-368. (Pubitemid 44244927)
48. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-470. (Pubitemid 47312140)
49. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R 2009 BRAF Mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982.
50. Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M 2009 Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 69:3042-3051.
51. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G 2008 Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:3041-3046. (Pubitemid 351723664)
52. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42.
53. Kwong L, Chin L, Wagner SN 2007 Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol 23:99-129.
54. Friday BB and Adjei AA 2008 Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346.
55. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
56. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713.
57. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
58. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387.
59. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693. (Pubitemid 41159359)
60. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle- Teijeiro J, Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207. (Pubitemid 41743711)
61. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170. (Pubitemid 46424056)
62. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M 2007 High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 92:2387-2390. (Pubitemid 46997152)
63. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008 93:3106-3116.
64. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogenactivated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278-284.
65. Furuya F, Lu C, Willingham MC, Cheng SY 2007 Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28:2451-2458. (Pubitemid 350238946)
66. Liu D, Hou P, Liu Z, Xing M 2009 Genetic alterations in the PI3K/Akt signalling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mTOR. Cancer Res (in press).
67. Hou P, Liu D, Ji M, Liu Z, Engles JM, Wahl RL, Xing M 2009 Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One 4:e6200.